Honasa Q2 FY26: PAT turns around, H1 profit nearly 4x; to buy 25% in Fang Oral Care

Profit growth above 25%Results restatedResults View source PDF Explain this filing

HONASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹283.95

prior close

₹300.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+1.8% vs market

Personal Care peers, median of 12sector-0.6%+2.1% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Smallcap 250 and 2.1 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.5

15m

+0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4-0.4+1.8-0.6+2.1

Next day

+2.4-0.2+2.6+0.1+2.3

+4.9+0.5+4.5+0.7+4.3

+1.1-0.6+1.6-0.4+1.5

+2.9-1.0+3.9-0.9+3.8

+2.1-1.1+3.2-1.2+3.3

+2.1-2.9+5.1-2.7+4.8

15d

-2.3-3.1+0.9-1.7-0.6

-10.2-3.9-6.3-2.5-7.7

+2.3-5.3+7.7-3.5+5.8

+5.2-6.6+11.8-2.5+7.7

UpDownMarket · Nifty Smallcap 250Sector · Personal Care peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Honasa Q2 FY26 standalone revenue rose 16.8% YoY to Rs 526.7 crore; H1 at Rs 1,110 crore, up 11.7%. Q2 PAT swung to Rs 38.3 crore profit from Rs 19.6 crore loss; H1 PAT Rs 78.2 crore versus Rs 19.7 crore earlier (nearly 4x). Consolidated H1 PAT Rs 80.6 crore versus Rs 21.7 crore. Board separately approved 25% stake buy in Couch Commerce (Fang Oral Care) for up to Rs 10 crore. Prior periods restated for amalgamation of two subsidiaries. Auditor gave unmodified review report.

Likely market impact

Strong profit turnaround in H1 with PAT nearly 4x YoY; minor Fang Oral Care acquisition diversifies portfolio. Results restated for amalgamation.